Back to Search
Start Over
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
- Source :
-
Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2013 Jan; Vol. 28 (1), pp. 51-6. - Publication Year :
- 2013
-
Abstract
- Background and Aim: Although the anti-hepatitis C virus (HCV) effect of statins in vitro and clinical efficacy of fluvastatin combined with Pegylated interferon (PEG-IFN)/ribavirin therapy for chronic hepatitis C (CHC) have been reported, the details of clinical presentation are largely unknown. We focused on viral relapse that influences treatment outcome, and performed a post-hoc analysis by using data from a randomized controlled trial.<br />Methods: Thirty-four patients in the fluvastatin group and 33 patients in the non-fluvastatin group who achieved virological response (complete early virological response [cEVR] or late virological response [LVR]) with PEG-IFN/ribavirin therapy were subjected to this analysis. Factors contributing to viral relapse were identified by using multiple logistic regression analysis.<br />Results: Relapse rate in patients with cEVR was significantly lower in the fluvastatin group (2 of 23, 8.7%) than in the non-fluvastatin group (9 of 26, 34.6%; P = 0.042). The use of fluvastatin decreased relapse rate in patients with LVR (27.3% vs 57.1%), though not significantly. Overall, relapse rate was significantly lower in the fluvastatin group (14.7%; 5 of 34) than in the non-fluvastatin group (39.4%; 13 of 33; P = 0.027). Multivariate analysis identified absence of fluvastatin (P = 0.027, odds ratio [OR] = 3.98, 95% confidence interval [CI] = 1.05-15.11) and low total ribavirin dose (P = 0.002, OR = 2.41, 95% CI = 1.38-4.19) as independent factors contributing to relapse.<br />Conclusion: The concomitant addition of fluvastatin significantly suppressed viral relapse, resulting in the improvement of sustained virological response rate, in PEG-IFN/ribavirin therapy for CHC patients with HCV genotype 1b and high viral load.<br /> (© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Confidence Intervals
Drug Therapy, Combination
Female
Fluvastatin
Hepatitis C, Chronic blood
Humans
Interferon alpha-2
Interferon-alpha therapeutic use
Logistic Models
Male
Middle Aged
Multivariate Analysis
Odds Ratio
Polyethylene Glycols therapeutic use
RNA, Viral blood
Recombinant Proteins therapeutic use
Recurrence
Ribavirin therapeutic use
Antiviral Agents therapeutic use
Fatty Acids, Monounsaturated therapeutic use
Hepacivirus genetics
Hepatitis C, Chronic drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Indoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1440-1746
- Volume :
- 28
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of gastroenterology and hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 22989264
- Full Text :
- https://doi.org/10.1111/j.1440-1746.2012.07267.x